The Food and Drug Administration (FDA) has approved Emblaveo™ (aztreonam and avibactam), in combination with metronidazole, for patients 18 years and older who have limited or no alternative ...
Hosted on MSN1mon
AbbVie gets FDA approval for antibiotic treatment Emblaveo (update)AbbVie (NYSE:ABBV) said it has received FDA approval for the intravenous antibiotic treatment Emblaveo, which was co-developed with Pfizer (NYSE:PFE). The FDA approved Emblaveo, a combination of ...
Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be approved by the FDA for complicated intra-abdominal infections with limited ...
AbbVie's combination antibiotic Emblaveo has gotten federal approval to treat complicated intra-abdominal infections, making it the first and only such therapy approved to fight antimicrobial ...
AbbVie announced that the US Food and Drug Administration (FDA) has approved Emblaveo (aztreonam and avibactam), as the first and only fixed-dose, intravenous, monobactam/ß-lactamase inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback